Browsing Tag
Craig Collard
1 post
Heron Therapeutics (Nasdaq: HRTX) withdraws 2026 guidance as CINVANTI patent ruling reshapes plan
Heron Therapeutics withdrew 2026 guidance and cut $13.5m of Hercules debt after a June Delaware ruling on CINVANTI, with monthly covenants now running through 2027.